Neuroendocrine Carcinoma clinical trials

Explore recruiting neuroendocrine carcinoma clinical trials.

Recruiting neuroendocrine carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Neuroendocrine Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Italian multicenter phase II trial of Metronomic Temozolomide in unfit patients with advanced neuroendocrine neoplasms (NENs): MeTe study

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

PRODIGE 69 – FOLFIRINEC - FOLFIRINOX versus PLATINUM - ETOPOSIDE as first line chemotherapy for metastatic grade 3 poorly differentiated neuroendocrine carcinoma of gastro entero pancreatic and unknown primary associated with molecular profiling for therapeutic targets & predictive biomarkers identification

France

Therapeutic exploratory (Phase II) EU CTIS Study details

DAREON™-7: A study to test how well different doses of BI 764532 in addition to chemotherapy are tolerated by people with advanced neuroendocrine cancers

Spain, Belgium, Germany, France, Sweden, Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

A phase II, open-label, multicenter trial to investigate the clinical activity and safety of Cabozantinib in combination with avelumab in patients refractory to standard chemotherapy with advanced neuroendocrine neoplasias G3 (NEN G3)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

PRODIGE 113 (FFCD 2314) – REWENEC – 01 STUDY Randomized trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI with a hybrid synthetic control arm in second line treatment of metastatic neuroendocrine carcinoma of gastro-enteropancreatic or unknown origin. Phase II comparative randomized study – multicentric

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A multicentre phase II, single arm study of Durvalumab (MEDI 4736) with Carboplatin plus Etoposide for 4 cycles followed by Durvalumab maintenance in patients with metastatic pulmonary large-cell neuroendocrine carcinoma (LCNEC) – DUPLE trial

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Neuroendocrine Carcinoma trials by city

Neuroendocrine Carcinoma in Toronto Neuroendocrine Carcinoma in Vancouver Neuroendocrine Carcinoma in Montreal Neuroendocrine Carcinoma in Calgary Neuroendocrine Carcinoma in Edmonton Neuroendocrine Carcinoma in Ottawa Neuroendocrine Carcinoma in Winnipeg Neuroendocrine Carcinoma in Quebec City Neuroendocrine Carcinoma in Hamilton Neuroendocrine Carcinoma in Kitchener Neuroendocrine Carcinoma in London Neuroendocrine Carcinoma in Halifax Neuroendocrine Carcinoma in New York Neuroendocrine Carcinoma in Los Angeles Neuroendocrine Carcinoma in Chicago Neuroendocrine Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease